摘要
目的：本研究旨在观察食管癌和贲门癌术后患者同步化疗中配合脾多肽治疗对患者免疫功能的影响。方法2013年3月至2014年1月在我院接受手术治疗且经术后病理证实的食管癌和贲门癌患者60例，按照随机数字表法分为实验组和对照组，每组各30例。实验组患者术后接受标准化疗方案治疗同时接受脾多肽治疗，对照组患者术后只接受标准化疗方案治疗。结果化疗前两组患者血CD3、CD4、CD4／CD8比较差异均无统计学意义（ P 均＞0．05）。经过2个周期化疗后，实验组血 CD3[（76．08±8．04）％]、CD4[（42．91±7．73）％]、CD4／CD8（1．31±0．21）均明显高于对照组的CD3[（38．58±6．40）％]、CD4[（42．91±7．73）％]、CD4／CD8（1．16±0．22），两组比较差异均有统计学意义（P值分别为0．037、0．022、0．008）；实验组患者生存质量优于对照组（ P＝0．038）；WBC维持在正常范围的患者比例明显高于对照组（80．0％与53．3％，P＝0．028）；实验组患者化疗过程中消化系统不良反应均低于对照组，两组比较差异均有统计学意义（反酸、烧心：26．7％与63．3％， P＝0．004，恶心、呕吐：33．3％与73．3％， P＝0．002，食欲减退：46．7％与80．0％，P＝0．007）。结论食管癌和贲门癌术后化疗患者配合脾多肽治疗可以提高机体免疫力，提高患者化疗过程中和化疗后的生活质量。
Objective To investigate the effect of synchronous chemotherapy combined with spleen polypeptide on immune function in patients with esophageal cancer and cardiac cancer after operation. Methods Sixty postoperative patients of esophageal and esophagogastric junction carcinoma were collected in the Fourth Hospital of Hebei Medical Universitythe from March 2013 to January 2014,and were randomly divided into two groups,including 30 cases were treated with simple chemotherapy as control group,and the other 30 cases were treated with chemotherapy combined with lineal polypeptides as experimental group. Results There were no significant differences in terms of CD3,CD4 and CD4/CD8 between the two groups before operation（ P〉0. 05） . After two cycles of chemotherapy,the CD3,CD4,CD4/CD8 of experimental group were all significantly higher than the control group（（76. 08±8. 04）% vs. （38. 58±6. 40）%,（42. 91±7. 73）% vs. （42. 91±7. 73）%,1. 31 ±0. 21 vs. 1. 16±0. 22）,and the differences were significant（P=0. 037,0. 022,0. 008）. The survival quality of the experimental group was better than that of the control group （ P=0. 038 ） . The proportion of patients with WBC in the normal range of the experimental group was significantly higher than that in the control group （80. 0% vs. 53. 3%,P=0. 028）. The adverse reactions of the digestive system in the experimental group were lower than those in the control group, the difference was statistically significant between the two groups （ acid reflux and heartburn：26. 7% vs. 63. 3%,P=0. 004;nausea and vomiting：33. 3% vs. 73. 3%,P=0. 002;loss of appetite：46. 7% vs. 80. 0%,P=0. 007） . Conclusion The treatment of the patients with esophageal cancer and cardiac cancer after chemotherapy with spleen peptides can improve immunity,and improve the quality of life of patients after chemotherapy and chemotherapy.
出处
《中国综合临床》
2016年第7期640-642,共3页
Clinical Medicine of China
关键词
食管癌
贲门癌
脾多肽
化学治疗
T细胞亚群
Esophageal carcinoma
Cardiac carcinoma
Lineal polypeptides
Chemotherapy
T-cell subgroup
